Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene Signs up Hansoh in $101 Million Deal for Commercialization Rights to XPO1 Inhibitor

publication date: Aug 11, 2023

Shanghai Antengene out-licensed China commercialization rights for its XPO1 inhibitor, an approved therapy for multiple myeloma in China, to Hansoh Pharma in a deal worth up to $101 million in upfront and milestone payments. Antengene will continue to conduct all development work of Xpovio®, including distribution. Hansoh will be responsible for commercialization for which it will charge a service fee based on sales. Antengene will be eligible to receive $28 million in upfront payments and $73 million in milestones, plus it will record revenues from the drug. Hansoh Group is based in Shanghai. More details....

Stock Symbols: (HK: 6996) (HK: 3692)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here